SCHEMBL4289748

SCHEMBL4289748

CCOC(=O)c1ncn([C@H]2CCCC[C@H]2NC(=O)OCc2ccccc2)c1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.44
CYP19A1 P11511 1/20 0.42
ROCK2 O75116 1/20 0.42
CASP3 P42574 3/20 0.41
CPB1 P15086 1/20 0.41
EED O75530 1/20 0.41
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
BRD4 O60885 2/20 0.39
BRD2 P25440 2/20 0.39
BRD3 Q15059 2/20 0.39
FAAH O00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4282224 0.93 CYP19A1 (0.41) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL4285560 0.93 CYP19A1 (0.41) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL4296455 0.93 CYP19A1 (0.41) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL4296458 0.93 CYP19A1 (0.41) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL13705066 0.93 CYP19A1 (0.41) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL4296461 0.93 CYP19A1 (0.41) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL4283612 0.92 CYP19A1 (0.41) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL4284065 0.88 MEN1 (0.38) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL4285804 0.87 MEN1 (0.38) CYP19A1EEDTSHRALDH1A1GAA
SCHEMBL4290973 0.87 TSHR (0.38) CYP19A1EEDTSHRALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT EPHX1 747/4885CYP19A1 705/4885ROCK2 792/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT EPHX1 747/4885CYP19A1 705/4885ROCK2 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.